ArticleJournal of gastrointestinal cancer2012
A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib.
Article in Journal of gastrointestinal cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026Review
- A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series.Cancer medicine · 2026Review
- Marked response to dabrafenib plus trametinib in a patient with BRAF V600E-mutant pancreatic hepatoid carcinoma: a case report and systematic analysis of 57 cases.Frontiers in oncology · 2026Article
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- Focal Hepatocellular Carcinoma in Pancreas.Journal of medical cases · 2024Article
- Case report and literature analysis: pancreatic hepatoid carcinoma with multiple lymph node metastases progressing to liver metastasis after pancreaticoduodenectomy.Frontiers in oncology · 2024Article
- A case report of two instances of colorectal hepatoid adenocarcinoma, accompanied by a comprehensive literature review.Journal of cancer research and clinical oncology · 2023Review
- Extended pancreatoduodenectomy with portal vein and inferior vena cava resection and reconstruction combined with sorafenib for hepatoid carcinoma of the pancreas: a strategy of superextended surgery combined with targeted therapy.Hepatobiliary surgery and nutrition · 2023Article
- Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report.World journal of clinical cases · 2022Article
- Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report.World journal of clinical cases · 2022Article
- Surgical Resection of Pancreatic Hepatoid Carcinoma Followed by Combined Transarterial Chemoembolization and Immunotherapy: A Case Report.OncoTargets and therapy · 2021Article
- Extra-Hepatic Hepatoid Carcinomas in Female Reproductive System: Three Case-Reports with a Literature Review.Cancer management and research · 2021Article
- Hepatoid carcinoma of the pancreas: A case report and review of the literature.World journal of clinical cases · 2020Article
- Pure pancreatic hepatoid carcinoma: a surgical case report and literature review.Surgical case reports · 2019Article
- Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review.Medicine · 2018Review
- Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide.Oncology letters · 2018Article
- Article
- Metastatic hepatoid carcinoma of ovarian origin - a case report from northern Pakistan.Gynecologic oncology reports · 2017Article
- A hepatoid carcinoma of the pancreatic head.Surgical case reports · 2016Article
- Liver metastasis from hepatoid adenocarcinoma of the stomach mimicking hepatocellular carcinoma: Dynamic computed tomography findings.World journal of gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatoid carcinoma (HC) is a rare histopathological tumor type with prominent features of hepatoid differentiation, and while most of the reported cases are of gastric origin, ten cases of pancreatic HC have been reported to date. The majority of HC cases are metastatic at presentation, mainly to the liver, lymph nodes, and lungs. They are aggressive, invading, and proliferating in the venous and lymphatic systems, with a behavior similar to that of hepatocellular carcinoma. Diagnosis is challenging: alpha-Fetoprotein, the most useful marker, is not always positive.
methodsWe present the first case of metastatic pancreatic HC treated with sorafenib, an oral multikinase inhibitor approved for advanced hepatocellular carcinoma that has antiangiogenic, pro-apoptotic, and raf-kinase inhibitory properties.
resultsThe patient, a 37-year-old male, was diagnosed with hepatoid carcinoma of the pancreas that had metastasized to liver, lungs, and lymph nodes. The cytokeratin (CK) profile was useful for the diagnosis: Both the hepatoid and adenocarcinoma components of the tumors were CK18+, CK19+, and CK20+/-, whereas normal and neoplastic hepatocytes are CK18+, CK19-, and CK20-. Amylase, lipase, and liver enzyme levels were elevated, but bilirubin was normal. Treatment with sorafenib resulted in more than 7 months of progression-free survival. Therapy was discontinued after 8 months when his bilirubin level increased dramatically. Signs of liver failure resolved temporarily with insertion of a biliary stent, but his condition deteriorated and he died 3 months later, 1 year after diagnosis.
conclusionIn the absence of evidence-based experience with this rare and aggressive tumor and given its similarities with hepatocellular carcinoma, sorafenib should be considered as a possible treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.